134 related articles for article (PubMed ID: 31732522)
1. A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.
Dizier B; Callegaro A; Debois M; Dreno B; Hersey P; Gogas HJ; Kirkwood JM; Vansteenkiste JF; Sequist LV; Atanackovic D; Goeman J; van Houwelingen H; Salceda S; Wang F; Therasse P; Debruyne C; Spiessens B; Brichard VG; Louahed J; Ulloa-Montoya F
Clin Cancer Res; 2020 Apr; 26(7):1725-1735. PubMed ID: 31732522
[TBL] [Abstract][Full Text] [Related]
2. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
3. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
4. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
Zuo S; Wei M; Zhang H; Chen A; Wu J; Wei J; Dong J
J Transl Med; 2019 May; 17(1):152. PubMed ID: 31088477
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P; Gutzmer R; Ascierto PA; Maio M; Grob JJ; Murawa P; Dreno B; Ross M; Weber J; Hauschild A; Rutkowski P; Testori A; Levchenko E; Enk A; Misery L; Vanden Abeele C; Vojtek I; Peeters O; Brichard VG; Therasse P
Ann Oncol; 2016 Oct; 27(10):1947-53. PubMed ID: 27502712
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Versluis JM; Blankenstein SA; Dimitriadis P; Wilmott JS; Elens R; Blokx WAM; van Houdt W; Menzies AM; Schrage YM; Wouters MWJM; Sanders J; Broeks A; Scolyer RA; Suijkerbuijk KPM; Long GV; Akkooi ACJV; Blank CU
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677880
[TBL] [Abstract][Full Text] [Related]
8. Characterizing heterogeneity of non-small cell lung tumour microenvironment to identify signature prognostic genes.
Mi K; Chen F; Qian Z; Chen J; Lv D; Zhang C; Xu Y; Wang H; Zhang Y; Jiang Y; Shang D
J Cell Mol Med; 2020 Dec; 24(24):14608-14618. PubMed ID: 33184998
[TBL] [Abstract][Full Text] [Related]
9. Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma.
Qu Y; Zhang S; Zhang Y; Feng X; Wang F
Virchows Arch; 2021 May; 478(5):943-959. PubMed ID: 33179141
[TBL] [Abstract][Full Text] [Related]
10. Identifying prognostic biomarkers of non-small cell lung cancer by transcriptome analysis.
Xiong Y; Feng Y; Qiao T; Han Y
Cancer Biomark; 2020; 27(2):243-250. PubMed ID: 32083573
[TBL] [Abstract][Full Text] [Related]
11. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.
Roepman P; Jassem J; Smit EF; Muley T; Niklinski J; van de Velde T; Witteveen AT; Rzyman W; Floore A; Burgers S; Giaccone G; Meister M; Dienemann H; Skrzypski M; Kozlowski M; Mooi WJ; van Zandwijk N
Clin Cancer Res; 2009 Jan; 15(1):284-90. PubMed ID: 19118056
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of long non-coding RNA HOTTIP in early-stage non-small-cell lung cancer.
Navarro A; Moises J; Santasusagna S; Marrades RM; Viñolas N; Castellano JJ; Canals J; Muñoz C; Ramírez J; Molins L; Monzo M
BMC Pulm Med; 2019 Feb; 19(1):55. PubMed ID: 30819158
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
14. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
15. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
Peretti U; Ferrara R; Pilotto S; Kinspergher S; Caccese M; Santo A; Brunelli M; Caliò A; Carbognin L; Sperduti I; Garassino M; Chilosi M; Scarpa A; Tortora G; Bria E
Respir Res; 2016 Aug; 17(1):105. PubMed ID: 27561692
[TBL] [Abstract][Full Text] [Related]
16. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
17. Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†.
Chiappetta M; Leuzzi G; Sperduti I; Bria E; Mucilli F; Lococo F; Spaggiari L; Ratto GB; Filosso PL; Facciolo F
Eur J Cardiothorac Surg; 2019 Mar; 55(3):405-412. PubMed ID: 30202953
[TBL] [Abstract][Full Text] [Related]
18. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
[TBL] [Abstract][Full Text] [Related]
19. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
